In an earlier post, I described my DIGR® method of root cause analysis (RCA):
Define
Is – Is Not
Go Step By Step
Root Cause
In this post, I wanted to look more at Go Step By Step and why it is so powerful.
“If you can’t describe what you’re doing as a process, you don’t know what you’re doing” – a wonderful quote from W. Edwards Deming! And there is a lot of truth to it. In this blog, I’ve been using a hypothetical situation to help illustrate my ideas. Consider the situation where you are the Clinical Trial Lead on a vaccine study. Information is emerging that a number of the injections of trial vaccine have actually been administered after the expiry date of the vials. This has happened at several sites. You’ve taken actions to contain the situation for now. And have started using DIGR® to try to get to the root cause. It’s already brought lots of new information out and you’ve got to Go Step By Step. As you start to talk through the process, it becomes clear that not everyone has the same view of what each role in the process should do. A swim-lane process map for how vaccine should be quarantined shows tasks split into roles and helps the team to focus on where the failures are occurring:
In going step-by-step through the process, it becomes clear that the Clinical Research Associates (CRAs) are not all receiving the emails. Nor are they clear what they should do with them when they do receive them. The CRA role here is really a QC role however – the primary process takes place in the other two swimlanes. And it was the primary process that broke down – the email going from the Drug Management System to the Site (step highlighted in red).
So we now have a focus for our efforts to try to stop recurrence. You can probably see ways to redesign the process. That might work for future clinical trials but could lead to undesired effects in the current one. So a series of checks might be needed. For example, sending test emails from the system to confirm receipt by site and CRA or regular checks for bounced emails. Ensuring CRAs know what they should do when they receive an email would also help – perhaps the text in the email can be clearer.
By going step-by-step through the process as part of DIGR®, we bring the team back to what they have control of. We have moved away from blaming the pharmacists or the nurses at the two sites. Going down the blame route is never good in RCA as I will discuss in a future post. Reviewing the process as it should be also helps to combat cognitive bias which I’ve mentioned before.
As risk assessment, control and management is more clearly laid out in ICH GCP E6 (R2), process maps can help with risk identification and reduction too. To quote from section 5.0 “The sponsor should identify risks to critical trial processes and data”. Now we’ve discovered a process that is failing and could have significant effects on subject safety. By reviewing process maps of such critical processes, consideration can be given to the identification, prioritisation and control of risks. This might involve tools such as Failure Mode and Effects Analysis (FMEA) and redesign where possible in an effort to mistake-proof the process. This helps to show one way how RCA and risk connect – the RCA led us to understand a risk better and we can then put in controls to try to reduce the risk (by reducing the likelihood of occurrence). We can even consider how, in future trials, we might be able to modify the process to make similar errors much less likely and so reduce the risk from the start. This is true prevention of error.
In my next post I will talk about how (not) to ‘automate’ a process.
Text: © 2017 Dorricott MPI Ltd. All rights reserved.
DIGR® is a registered trademark of Dorricott MPI Ltd.